Sanofi Bets Big On IO With Synthorx Buy
Expects Interleukin-2 To Be Foundation Of Future IO-IO Combos
Executive Summary
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
You may also be interested in...
Stockwatch: Hopes For Fireworks But Expectations For Goldilocks
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
